Triple digit growth in EMEA as pharma companies embrace rfxcel’s full-service approach to FMD compliance

June 15, 2018 – San Ramon, CA – International provider of SaaS-based track and trace and serialisation solutions, rfxcel, today announces its continued successful expansion in the UK and EMEA, with triple digit percentage revenue growth since 2017. Increasing numbers of pharmaceutical companies welcome rfxcel’s inclusive approach to helping its clients successfully achieve the EMVO (European Medicines Verification Organisation) onboarding process as part of their compliance with the Falsified Medicines Directive (FMD).

rfxcel now boasts on-the-ground sales, delivery and customer support teams across four continents, including its US headquarters, an EMEA head office in the UK, and bases in Latin America, India and Japan as well as local capability in Russia. Sales headcount has increased by 300% and delivery and support teams by 350% over the same period. Working relationships with major global business partners have also been established, further extending rfxcel’s complementary offerings.

Mark Davison, rfxcel Senior Director of Operations Europe, comments: “rfxcel prides itself on our rapid, full-service implementation model, which provides a great opportunity to marketing authorisation holders (MAHs) who need move quickly.  With the February 2019 FMD deadline rapidly approaching, companies are recognising that they need an experienced provider who can not only support them through the initial implementation but will go the extra mile to ensure the success of their solution, from data integrity to testing the end-to-end connectivity, reporting and interaction with business partners. Many customers have already registered rfxcel as their EMVO provider.  With our established links to the European Medicines Verification System (EMVS) for MAHs, as well as national systems (NMVSs) for distributors and dispensers, we provide an award-winning solution for the whole supply chain impacted by FMD.”

Mark Davison further comments: “As an additional benefit, rfxcel’s full-service implementation model, enables companies to also avoid the hidden costs and additional resources required by other solution providers to onboard their trading partners.”

Glenn Abood, Chairman and CEO, rfxcel, adds: “Patient safety is at risk if people can’t verify the validity of the drug. rfxcel’s aim is to help the global pharmaceutical industry mitigate that risk and protect their patients and products. With integrity at the heart of our business – from helping clients with their data integrity, to our commitment to our customers – we help secure the supply chain, bring visibility in product distribution, enable compliance with government regulations, and ensure patient safety. We are immensely proud that this is an ethos that is being recognised and welcomed by the industry.”

On 20th June 2018, rfxcel is hosting a webinar entitled: ‘The EU Falsified Medicines Directive: Data Integrity in a Serialised World’, covering aspects of FMD compliance including why data integrity is only as good as the weakest link; how data errors can occur in validated systems; why active error checking is needed; what the regulators are planning; and how organisations can prepare.

For more information or to learn more about the requirements surrounding the European Union’s Falsified Medicines Directive (FMD) or rfxcel’s solutions to meet these needs, please contact us.

rfxcel Covers the Cost of EMVO On-boarding Fees

May 23, 2018 – San Ramon, CA – rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.

Manufacturers who wish to participate in this great opportunity should contact rfxcel (eu@rfxcel.com) for details of the solution and terms of the offer. They then simply need to name rfxcel as their Gateway Provider when registering on the EMVO portal (https://emvo-medicines.eu/pharmaceutical-companies) before June 15th 2018. When we conclude a software contract, the cost of the EMVO fee will be absorbed by rfxcel as a discount.

With EMVO onboarding fees increasing by 50% after June 15th 2018, rfxcel is taking a significant step in helping EMVO to accelerate its onboarding programme and MAHs to meet their requirements under the Falsified Medicines Directive in a timely manner.

rfxcel provides a full-service, fixed price approach that gets MAHs ready to exchange data with EMVO quickly and efficiently. We manage the end to end process from EMVO onboarding to connection, reporting and interaction with business partners such as contract manufacturers (CMOs). This enables even very small MAH companies to comply with FMD obligations with minimum resource and cost impact.

“Our initiative to cover the cost of the EMVO onboarding fee, paired with our rapid, full-service implementation, provides a great opportunity to MAHs who need move quickly.  With rfxcel they also avoid the hidden costs and additional resources required by other solution providers to onboard their trading partners”, said Mark Davison, rfxcel Senior Director of Operations Europe.

To learn more about the requirements surrounding the European Union’s Falsified Medicines Directive (FMD) or rfxcel’s solutions to meet these needs, please contact us.

*The offer relates to EMVO (one-time) onboarding fees only. It does not include any initial or annual fees that may be payable to national medicine verification organisations (NMVOs).

For more information contact us:

Herb Wong, VP Marketing

hwong@rfxcel.com

rfxcel.com

 

rfxcel Drives LATAM Expansion

rfxcel announced today that they will expand their capability to enable LATAM Life Science(s) organizations to meet serialization and regulatory compliance requirements throughout Latin America and around the globe.

rfxcel is excited to announce the addition of Vinicius (Vinnie) Bagnarolli to their growing team of industry experts. Vinnie will be serving as the Commercial Director for Latin America. He will be responsible for driving rfxcel’s overall sales strategy and offerings to both existing and new clients throughout the region.

Vinnie joins rfxcel with an impressive resume; he has played leading roles with organizations such as Dell and Oracle. Prior to studying International Business Management in Canada, Vinnie managed a “technology stack” (Database, Middleware and Business Intelligence) division in São Paulo, Brazil that served both the Health Care and Life Sciences industries. Vinnie credits his success to his belief in educating both himself and his customers to be a reference in the industry. Most recently, he managed a Healthcare Global Business Unit and reported directly to the VP of Sales at Oracle’s headquarters in Redwood City, CA.

“rfxcel’s mission is a great fit for Latin America” says Vinnie. “We need companies that want to thrive and who want to help people – rfxcel’s expansion into LATAM and around the globe is making a positive impact on society.” Vinnie went on to say “Being part of an organization that puts their customers first and helps ensure products are safer and free from counterfeits is something that I am proud to be a part of.”

As the pioneer and a leader of track and trace solutions for the Life Sciences industry, rfxcel provides a robust product platform as well as a full-service implementation/support model, that ensures customer success, patient safety and peace of mind. rfxcel would like to officially welcome Vinnie to the Team, and we look forward to the opportunity to help fulfill the serialization and compliance needs throughout Latin American countries.

 

 

rfxcel launches fully integrated Warehouse Edge System with partner Navitas Life Sciences

rfxcel Corporation, the global serialization and track and trace provider for the Life Sciences industry, announced today that its industry-leading traceability system now has fully integrated “edge” functionality for warehouse, distribution and re-work operations (Warehouse Edge System).

rfxcel has extended its successful partnership with Navitas Life Sciences (“Navitas”) to provide a seamless and efficient solution to enable customers to meet obligations under the European Falsified Medicines Directive (EU FMD), US Drug Supply Chain Security Act (DSCSA) and other serialization requirements. The advanced and simple-to-use features of the Navitas traceREADY edge system are now completely integrated with rfxcel’s Traceability System (rTS).

“The new capability provides a truly full-service, one-stop capability for distributors, manufacturers, and the many companies who have a complex hybrid of both operations. Edge and re-work activities during manufacturing and supply can now be handled directly and smoothly in our system. As global regulations increasingly affect distribution as well as manufacture of medicines, we are positioned to offer what customers need” said Glenn Abood, CEO of rfxcel.

“We are pleased to strengthen our successful relationship with rfxcel. Our fully integrated solution now provides customers with significant cost and performance efficiencies. We look forward to taking our solution to the global market and deliver enhanced value to our customers” said Ram Yeleswarapu, President, Navitas Life Sciences.

In the complex world of traceability, rfxcel is refreshingly easy to work with. Transparent pricing and robust private cloud architecture allows customers to get compliant quickly and at predictable cost. They can then focus on their core business without the constant risk assessment and revalidation required by some providers.

Learn more about Serialisation/Serialization and their edge system by booking a 30 min demo with the IT team.

rfxcel Solution Recognized in HDA Distribution Management Award

March 6, 2018 – San Ramon, CA – rfxcel, the world’s leader in supply chain track and trace for the Pharmaceutical industry is one of two companies recognized by the HDA (Healthcare Distribution Alliance) for “…:efforts to improve the efficiency, effectiveness and safety of the healthcare supply chain through successful trading partner initiatives.”

“The award highlights innovative collaborations between distributors and manufacturers that enhance processes, reduce costs and leverage advanced technologies or logistical practices. Recipients are models for leadership and innovation in the pharmaceutical distribution industry and demonstrate the power of successful trading partner relationships .“ HDA Distribution Management Award

rfxcel’s Environmental Monitoring (EM) solution, was awarded Merit Finalist by the HDA for our work to enable real-time visibility of the Pharmaceutical supply chain via IOT (Internet of Things) technology.  The EM solution was piloted with a global manufacturer to track high-value pharmaceutical shipments – delivering real-time location and temperature data across 24 domestic and international locations.

“We at rfxcel are extremely excited about this award from the HDA.  It is recognition not only of our innovation but our commitment to partnering with the HDA and other industry leaders.” said, Glenn Abood, CEO of rfxcel.  

During the pilot, the rfxcel EM solution identified temperature excursions in real-time and alerted the manufacturer to these risks.  This allowed the manufacturer to take immediate action with their logistics provider and protect the integrity of their products. The solution also identified shipments which were improperly delivered to holding locations that were not approved to handle the products.  These improper deliveries were corrected in real-time avoiding potential damage to the high-value products.

“Today, many pharmaceutical companies are focused on meeting near-term serialization and compliance requirements such as Europe’s FMD (Falsified Medicines Directive), United State’s DSCSA (Drug Supply Chain Security Act), and many other governmental requirements. Our EM solution allows companies to extend the value of their compliance and serialization investment to gain new business value that was previously unavailable. Many companies talk about ‘Value Beyond Compliance’ but today, we have demonstrated that we can deliver on this commitment.” said Jack Tarkoff, Chief Strategy Officer of rfxcel.

As the pioneer and leader in traceability solutions for the Life Sciences industry, rfxcel provides its customers with a robust and sophisticated platform with a low total-cost-of-ownership. The EMVO certification – combined with a recent $30M growth capital infusion, the acquisition of Frequentz assets, and important key hires in Europe – widens the Company’s lead as the most versatile player in the industry.

To learn more about the HDA Distribution Management Award, visit:https://www.hda.org/about/industry-recognition/dma

If you would like to receive more details or see a demo of rfxcel’s Environmental Monitoring (EM) solution, please contact us at: https://www.rfxcel.com/contact-rfxcel/

 

For more information contact us:

Herb Wong, VP Marketing

hwong@rfxcel.com

rfxcel.com

 

About rfxcel:

rfxcel is the leading provider of SaaS-based track and trace solutions. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.

To learn more here: Serialization Software

HDA.Award.rfxcel.traceability

DCC Vital selects rfxcel as a serialisation solution provider

Serious About Serialisation: DCC Vital Selects rfxcel as a EU Falsified Medicines Directive and Serialisation Solution Provider

February 21, 2018 – San Ramon, CA, – rfxcel Corporation, a customer-focused serialisation and track and trace provider for the Life Sciences industry, announced today that DCC Vital, a manufacturer headquartered in Dublin, Ireland, has selected rfxcel to meet its European Falsified Medicines Directive (EU FMD) serialisation requirements.

As a European manufacturer of pharmaceuticals and medical devices, and a logistics provider in the UK, DCC Vital prides themselves in their ability to deliver solutions that will make a difference to patient care.   Over the past 5 years, DCC Vital has more than doubled the scale of their business to create a focused support system for their customers in Europe, and most recently have been gaining an increased presence worldwide.  As DCC Vital continues to expand their footprint internationally, the company needed a serialisation platform that could accommodate their diverse product offering, understand the need to keep their customers at the top of their focus, and allow them the flexibility to manage their environment based on their specifications.

“DCC Vital selected rfxcel for 3 reasons,” said Conor O’Shea, DCC Vital’s Head of Information Technology. “First, rfxcel is easy to work with.  Throughout the evaluation process, rfxcel was very responsive and provided clear answers to our questions.  Second, rfxcel offers a simple pricing model that is straight forward & transparent.  Finally, rfxcel offers a customer focused architecture that allows us to manage a validated environment according to our quality standards and schedule.”

Relentless commitment to customer success and continuous innovation ensures that rfxcel’s customers meet their requirements and protect their consumers. “We are seeing a paradigm shift in the industry through recent competitive conversions, due to a lack of personalized attention from vendors.”  said Glenn Abood, CEO of rfxcel.  “Manufacturers and the entire supply chain desire timely response, support, control, and pricing transparency from their solution providers.”

rfxcel offers fixed bid contracts, which ensures customers a clear insight into their pricing model, which is not the case when contracts are based on time and material bids.  “Customers are realizing that compliance with the Falsified Medicines Directive is just the starting point. In digitizing their complex supply chains, they are seeking out partners such as rfxcel who are willing to work with their specific needs and ways of working.  We help customers to succeed, without imposing inflexible processes or the frequent changes, risk assessments and re-validations involved with other vendors,” said Mark Davison, Senior Director of Operations Europe.

To learn more about the requirements surrounding EU Falsified Medicines Directive compliance or how to build a reliable and flexible serialisation platform that suits your needs, please visit our website at EU FMD Overview.

 

For more information contact us:

Herb Wong, VP Marketing

hwong@rfxcel.com

rfxcel.com

 

About rfxcel:

rfxcel is the leading provider of SaaS-based track and trace solutions. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.

To learn more here: Serialization Software

rTS 6.0: New Traceability Solution

rfxcel Traceability System 6.0:  New Traceability Solution Delivers Improved User Experience and Performance

 

San Ramon, February 7, 2018 – rfxcel, the leader in Life Science track and trace, and compliance systems, today announced the release of rfxcel Traceability System (rTS) 6.0.  The new traceability software delivers increased usability and performance which is powered by the new rTS 6.0 architecture and technology stack.

rTS 6.0 is built upon an enhanced architecture that provides greater scalability; allowing new features to be quickly added.  The new product gives users improved visibility into their supply chain via a new, highly responsive user interface (UI) and enhanced report features. Better search capabilities, menu navigation, event relationships, event notifications and alerts, and user configuration options have been added as part of the functional and UI improvements.  rTS 6.0 has been further optimized to deliver up to 3X performance improvement for critical processes.
To learn more, visit https://www.rfxcel.com/rfxcel-traceability-software-release-6-0/

“rTS 6.0’s cutting-edge architecture makes fast, easy data insight a reality for all customers. We’re incredibly proud of the work the rfxcel team has done to deliver this game-changing serialization and compliance technology, and most importantly, make it a seamless upgrade for our customers. rfxcel brings increased visibility and flexibility to supply chain traceability and product serialization, making data more assessable than ever before.” – Atul Mohidekar Chief Technology Officer at rfxcel.

The rTS 6.0 platform is designed to simplify and accelerate how customers can meet their compliance, serialization and track and trace requirements. By leveraging a new architecture and optimization techniques, customers can be confident that their investment will meet their current obligations and scale to meet their future needs.

To learn more about how we can help you with your needs for compliance, serialization, and track and trace, please visit us at www.rfxcel.com.

 

For more information, contact us:

Herb Wong, VP Marketing

hwong@rfxcel.com

rfxcel.com

 

About rfxcel:

rfxcel is the leading provider of SaaS-based track and trace solutions. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.

Technically Certified Connection Provider for EMVO

San Ramon, December 21, 2017 – rfxcel, a global Track & Trace company, has been confirmed as a EMVO Technically Certified Connection Provider. This provides the ability for pharmaceutical manufacturers to use rfxcel to connect their product master data to the European Hub, and to meet EU Falsified Medicine Directive (FMD) serialization and compliance requirements.

The European Medicines Verification System (EMVS) is a pan-European system operated by EMVO, to enable medicines to be verified at the point of dispensing. Under the terms of the EU Falsified Medicines Directive (FMD) from 9th February 2019, Marketing Authorization Holders within the FMD’s jurisdiction will be required to upload their product serialization data via the EMVS European Hub.

As a Technically Certified Connection Provider, rfxcel will enable Marketing Authorization Holders to capture and report their serialized data and related transactions to the European Hub via a validated, secure and cost-effective solution.

“This marks another major milestone for rfxcel as we continue to grow to meet the traceability and regulatory needs of the pharmaceutical industry in Europe.  We are excited to offer the most flexible and feature-rich solution to aid EMVO in its mission to protect the drug supply chain”, said Glenn Abood, CEO of rfxcel.

As the pioneer and leader in traceability solutions for the Life Sciences industry, rfxcel provides its customers with a robust and sophisticated platform with a low total-cost-of-ownership. The EMVO certification – combined with a recent $30M growth capital infusion, the acquisition of Frequentz assets, and important key hires in Europe – widens the Company’s lead as the most versatile player in the industry.

 

About rfxcel:

rfxcel is the leading provider of SaaS-based track and trace solutions. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.

 

Contact information:

Herb Wong, VP of Marketing

hwong@rfxcel.com

www.rfxcel.com

Leaders in Track and Trace Join rfxcel Executive Team

As part of rfxcel’s continued commitment to serve its global customers, rfxcel is pleased to announce that key leaders in track and trace join rfxcel Executive Team to drive global growth.

Jim Moore joins rfxcel as Senior VP of Corporate Development and GM of International Operations.

Jim has been an advisor to rfxcel, led the Company’s recent $30M capital raise with Kayne Partners, facilitated rfxcel’s entry into new geographies such as India and Europe, and completed the asset purchase from Frequentz. Jim has a unique track record of success in enterprise technology operations, analysis and investment banking.

“I am excited to bring my experience to drive international growth, partnerships, and M&A to further rfxcel’s mission to combat counterfeit pharmaceuticals, food and other products critical to the consumer”, said Moore.

“Jim has been invaluable in helping us formulate our capitalization and growth strategies and we are very pleased to have his experience and creativity added to our senior management team”, said Glenn Abood, CEO.

Simon Manley joins rfxcel as its new Commercial Director for Europe.

Simon will be responsible for driving rfxcel’s overall sales strategy and offerings to both existing and new clients in Europe. Simon will oversee marketing, strategic business partnerships and sales for Europe.

Simon joins from Oracle, where he was Sales Director for EMEA in the Health Sciences Global Business Unit, resulting in a huge expansion in sales growth across Europe, Middle East and Africa. Prior to this he was Vice President of Sales and Marketing at McKesson, a pharmaceutical distributor and the 5th highest revenue generating company in the US.

Commenting on the new appointment, Jim Moore said: “Simon brings relevant know-how to rfxcel and will be an asset to the management team. His knowledge of sales, customer satisfaction and international experience will be invaluable as we look to grow our presence in Europe.”

Manley commented: “I look forward to expanding rfxcel’s business both in Europe and globally. rfxcel’s commitment to customer success and continuous innovation ensures that customers meet their requirements and protect those who depend on them.  I am proud to be working with a team that can deliver all of this”

As the pioneer and leader in track and trace solutions for the Life Sciences market, rfxcel provides solutions to ensure customer success and secure their supply chain.

 

For more information contact us:

Herb Wong, VP Marketing

hwong@rfxcel.com

rfxcel.com

 

About rfxcel:

As the pioneer and leader in track and trace solutions for the Life Sciences, rfxcel provides solutions to improve the safety, quality, and security throughout the Life Sciences supply chain.